If all goes according to plan, Sanofi-Aventis plans to launch the highly anticipated diet pill Acomplia (rimonabant) in Britain and Germany in mid-summer. However, the U.S. Food and Drug Administration is not expected to act on approval of Acomplia for many months, and it is not likely to be available in the United States at least until sometime in 2007. It works by blocking pleasure sensitive receptors in the brain that are linked with compulsive behaviors such as overeating. Look for MySpace

Rimonabant | Acomplia, discovered and developed by Sanofi-Aventis, is thought to represent a new approach for the comprehensive management of cardiovascular risk factors. The compound has been studied to date in over 6,500 overweight and obese adults for up to 2 years.

Also check out Rimonabant - Acomplia Info Site

The biggest reason that the dangers on diet pills exist is that they are not really regulated. The law does not require a diet pill to be tested by the FDA before release to the public. The FDA will pull a diet pill product from the shelves if it shows to be dangerous, but by then you may already be taking that particular drug. So what are the side effects that can result from this lack of regulation?

Despite therapeutic advances in recent decades, cardiovascular disease remains the leading cause of mortality worldwide. Current treatments generally target risk factors individually, rather than providing a comprehensive management approach to such cardiovascular risks as dyslipidemia, abdominal obesity and insulin resistance, which comprise the metabolic syndrome.

Robust data replicated in 3 large studies showing consistent results

Significant reduction in waist circumference and weight
Weight-independent improvement in several metabolic variables
Achieved effacy at year 1, maintained at the end of year 2 with chronic therapy
Decreased number of patients with metabolic syndrome
Well tolerated
Improved quality of life

As the first selective CB1 blocker, the effects of rimonabant on lipid and glucose metabolism, insulin resistance and reduced intra-abdominal adiposity, evidenced by a reduction in waist circumference, have been studied. Abdominal obesity is recognized as a significant risk factor in the development of cardiovascular disease.

Rimonabant also has been studied by Sanofi-Aventis as an aid to smoking cessation based on studies for up to one year in over 6,500 smokers motivated to quit smoking.

Before taking any diet pill such as Rimonabant (Acomplia) - get the facts and check with your doctor.

Sources: Misc. Web Site News Releases

Rimonabant Acomplia | Diet Pill Acomplia | Acomplia Pill

TravelEurope | TravelSpain | TravelFrance

Diets Weight Loss Lose Weight Fat Reduction

Diet Info....

Rimonabant Acomplia | Diet Pill Acomplia | Acomplia Pill

Rimonabant or Acomplia is an anorectic anti-obesity (weight loss) drug.

Rimonabant Acomplia Diet Pill

Before taking any diet pill such as Rimonabant (Acomplia) - get the facts and check with your doctor.

Rimonabant Acomplia | Diet Pill Acomplia | Acomplia Pill

TravelEurope | TravelSpain | TravelFrance

Diets

Weight Loss

Lose Weight

Fat Reduction

Rimonabant or Acomplia is an
anorectic anti-obesity (weight loss) drug.